- Amgen's Tepezza receives approval from the U.K. for treating thyroid eye disease.
- Analysts forecast a potential average upside of 14.67% for Amgen's stock.
- Amgen holds an "Outperform" status with an estimated GF Value upside of 26%.
The U.K.'s drug authority has given the green light to Amgen's (AMGN) intravenous treatment, Tepezza, designed for adults suffering from moderate to severe thyroid eye disease. This approval comes after successful clinical trials that demonstrated significant improvements in both eye protrusion and double vision for patients.
Wall Street Analysts Forecast
According to the one-year price targets offered by 26 analysts, the average target price for Amgen Inc (AMGN) stands at $315.70, with projections ranging from a high of $400.00 to a low of $185.00. This average target suggests a potential upside of 14.67% from its current price of $275.30. Investors can access more detailed estimate data on the Amgen Inc (AMGN, Financial) Forecast page.
Additionally, based on consensus recommendations from 33 brokerage firms, Amgen Inc (AMGN) holds an average brokerage recommendation of 2.5, placing it in the "Outperform" category. The rating scale runs from 1 (Strong Buy) to 5 (Sell).
According to GuruFocus estimates, the projected GF Value for Amgen Inc (AMGN) in one year is $346.87. This indicates an expected upside of 26% from its current price of $275.30. The GF Value represents GuruFocus' assessment of the fair value a stock should trade at, calculated from historical trading multiples, past business growth, and future performance projections. Investors can explore more detailed data on the Amgen Inc (AMGN, Financial) Summary page.
